



Clinical trial results:

A Parallel-group Phase 4, Open-label, Two-arm Study to Assess the Safety and Efficacy of Intravitreal (IVT) Aflibercept with Proactive Customized Treatment Intervals in Patients 50 Years of Age with No Fluid Due to Choroidal Neovascularization (CNV) Lesions Secondary to Neovascular (wet) Age-related Macular Degeneration (nAMD) Following Treatment Initiation with Aflibercept

Summary

EudraCT number	2022-000690-73
Trial protocol	DE FR ES
Global end of trial date	11 July 2023

Results information

Result version number	v1 (current)
This version publication date	25 July 2024
First version publication date	25 July 2024

Trial information

Trial identification

Sponsor protocol code	BAY86-5321/21912
-----------------------	------------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT05473715
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Bayer AG
Sponsor organisation address	Kaiser Wilhelm Allee, Leverkusen, Germany, D-51368
Public contact	Therapeutic Area Head, Bayer AG, 49 30 300139003, clinical-trials-contact@bayer.com
Scientific contact	Therapeutic Area Head, Bayer AG, 49 30 300139003, clinical-trials-contact@bayer.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	11 July 2023
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	11 July 2023
Was the trial ended prematurely?	Yes

Notes:

General information about the trial

Main objective of the trial:

To assess whether 2 mg IVT aflibercept administered at a customized treatment interval (determined after the first extended treatment interval) is non-inferior to 2 mg IVT aflibercept administered according to a standard T&E regimen (initiated after the first extended treatment interval) in patients with no fluid following treatment initiation for nAMD

Protection of trial subjects:

The conduct of this clinical study met all local legal and regulatory requirements. The study was conducted in accordance with ethical principles that have their origin in the Declaration of Helsinki and the International Council for Harmonization guideline E6: Good Clinical Practice. Before entering the study, the informed consent was read by and explained to all the subjects. Participating subjects signed informed consent form and could withdraw from the study at any time without any disadvantage and without having to provide a reason for this decision. Only investigators qualified by training and experience were selected as appropriate experts to investigate the study drug.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	25 April 2023
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	United Kingdom: 1
Country: Number of subjects enrolled	Canada: 2
Worldwide total number of subjects	3
EEA total number of subjects	0

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0

Adolescents (12-17 years)	0
Adults (18-64 years)	0
From 65 to 84 years	1
85 years and over	2

Subject disposition

Recruitment

Recruitment details:

Study enrolled subjects in 2 countries, between 25 Apr 2023 (first subject first visit) and 11 Jul 2023 (termination date).

Pre-assignment

Screening details:

Four subjects were screened; 3 were randomized and treated.

Period 1

Period 1 title	Overall (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	Customized treatment interval

Arm description: -

Arm type	Experimental
Investigational medicinal product name	Aflibercept
Investigational medicinal product code	BAY 86-5321
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intravitreal use

Dosage and administration details:

2 mg intravitreal (IVT) injection, initial injection was at baseline, maintain injection interval is 16 weeks.

Arm title	Standard T&E
------------------	--------------

Arm description: -

Arm type	Active comparator
Investigational medicinal product name	Aflibercept
Investigational medicinal product code	BAY 86-5321
Other name	
Pharmaceutical forms	Injection
Routes of administration	Intravitreal use

Dosage and administration details:

2 mg IVT injection, initial injection is at baseline, maintain injection intervals is 8 weeks or adjusted in 2 weeks increments each time (up to a maximum of 16 weeks and minimum of 4 weeks).

Number of subjects in period 1	Customized treatment interval	Standard T&E
Started	2	1
Completed	0	0
Not completed	2	1
Trial terminate	2	1

Baseline characteristics

Reporting groups

Reporting group title	Overall
-----------------------	---------

Reporting group description: -

Reporting group values	Overall	Total	
Number of subjects	3	3	
Age Categorical			
Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	0	0	
Adolescents (12-17 years)	0	0	
Adults (18-64 years)	0	0	
From 65-84 years	1	1	
85 years and over	2	2	
Gender Categorical			
Units: Subjects			
Female	1	1	
Male	2	2	

End points

End points reporting groups

Reporting group title	Customized treatment interval
Reporting group description: -	
Reporting group title	Standard T&E
Reporting group description: -	

Primary: Change in best-corrected visual acuity (BCVA) (early treatment diabetic retinopathy study [ETDRS] letters)

End point title	Change in best-corrected visual acuity (BCVA) (early treatment diabetic retinopathy study [ETDRS] letters) ^[1]
-----------------	---

End point description:

Visual function was assessed using the ETDRS protocol (Early Treatment Diabetic Retinopathy Study Research Group, 1985). Visual acuity examiners must be certified to ensure consistent measurement of BCVA.

End point type	Primary
----------------	---------

End point timeframe:

From baseline to Week 36

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Descriptive statistics were done, no statistical analyses were performed.

End point values	Customized treatment interval	Standard T&E		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 ^[2]	0 ^[3]		
Units: Letter scale				
number (not applicable)				

Notes:

[2] - Study early terminated.

[3] - Study early terminated.

Statistical analyses

No statistical analyses for this end point

Secondary: Number of subjects with treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (TESAEs)

End point title	Number of subjects with treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (TESAEs)
-----------------	--

End point description:

AEs that occurred or worsened after the first injection of study drug and no later than 30 days after the last injection of study drug was considered as treatment-emergent adverse events (TEAEs).

End point type	Secondary
----------------	-----------

End point timeframe:

Up to weeks 36 and 52

End point values	Customized treatment interval	Standard T&E		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	2	1		
Units: Subjects	0	0		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of patients achieving pre-defined treatment intervals

End point title	Number of patients achieving pre-defined treatment intervals
End point description:	Pre-defined treatment intervals are: ≥ 4 , ≥ 8 , ≥ 10 , ≥ 12 , ≥ 14 , and 16 weeks.
End point type	Secondary
End point timeframe:	At Weeks 36 and 52

End point values	Customized treatment interval	Standard T&E		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 ^[4]	0 ^[5]		
Units: Subjects				

Notes:

[4] - Study early terminated.

[5] - Study early terminated.

Statistical analyses

No statistical analyses for this end point

Secondary: Change in BCVA (ETDRS letters)

End point title	Change in BCVA (ETDRS letters)
End point description:	
End point type	Secondary
End point timeframe:	From baseline to week 52

End point values	Customized treatment interval	Standard T&E		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 ^[6]	0 ^[7]		
Units: Letter score				
number (not applicable)				

Notes:

[6] - Study early terminated.

[7] - Study early terminated.

Statistical analyses

No statistical analyses for this end point

Secondary: Number of IVT aflibercept injections per patient up to Week 52

End point title	Number of IVT aflibercept injections per patient up to Week 52
End point description:	
Subject took aflibercept on study eye.	
End point type	Secondary
End point timeframe:	
Up to week 52	

End point values	Customized treatment interval	Standard T&E		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	2	1		
Units: Injections	1	1		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of IVT aflibercept injections per patient until Week 36

End point title	Number of IVT aflibercept injections per patient until Week 36	
End point description:		
Subject took aflibercept on study eye.		
End point type	Secondary	
End point timeframe:		
Up to week 36		

End point values	Customized treatment interval	Standard T&E		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	2	1		
Units: Injections	1	1		

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information^[1]

Timeframe for reporting adverse events:

After the first injection of study drug and no later than 30 days after the last injection of study drug, up to 78 days.

Adverse event reporting additional description:

Adverse event reporting for the deaths (all causes) considers all deaths that occurred at any time during the study before the last contact, up to 78 days.

Assessment type	Non-systematic
-----------------	----------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	26.0
--------------------	------

Reporting groups

Reporting group title	Standard T&E
-----------------------	--------------

Reporting group description: -

Reporting group title	Customized treatment interval
-----------------------	-------------------------------

Reporting group description: -

Serious adverse events	Standard T&E	Customized treatment interval	
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 1 (0.00%)	0 / 2 (0.00%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events	0	0	

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	Standard T&E	Customized treatment interval	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	0 / 1 (0.00%)	0 / 2 (0.00%)	

Notes:

[1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported.

Justification: No non-serious adverse events collected due to low number of participants.

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

The trial was terminated due to administrative reasons not related to efficacy or safety.

Notes: